Results 111 to 120 of about 75,512 (260)
The association of thrombocytopenia with haematological malignancy
This review article discusses the interplay of immune dysregulation, clonality, and immunosuppressive therapies in immune thrombocytopenia and how this links to the risk of misattribution versus the development of haematological malignancy. Unresolved questions and directions for future research are also discussed. Isolated thrombocytopenia is commonly
Abi Vijenthira +2 more
wiley +1 more source
Thrombocytosis is associated with an increased production of platelet‐derived microparticles from activated platelets, which contribute to vaso‐occlusion in sickle cell disease by perpetuating the cycle of inflammation, procoagulant state and endothelial dysfunction.
Giao N. Lê +3 more
wiley +1 more source
Advancing Immunotherapy in Chronic Lymphocytic Leukemia. [PDF]
Bieliński K +4 more
europepmc +1 more source
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat +5 more
wiley +1 more source
Atypical Cutaneous Manifestation Leading to the Diagnosis of Chronic Lymphocytic Leukemia. [PDF]
Memon M.
europepmc +1 more source
Summary Chronic lymphocytic leukaemia (CLL) presents a complex biological and clinical landscape, strongly influenced by the tumour microenvironment (TME). To better capture this heterogeneity, we have developed patient‐derived lymphoma spheroids from CLL samples (CLL‐PDLS), which recapitulate the cross‐talk between malignant cells and the autologous ...
Heribert Playa‐Albinyana +9 more
wiley +1 more source
Lymphocyte count and risk of chronic lymphocytic leukemia. [PDF]
Pahnke S +6 more
europepmc +1 more source
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco +21 more
wiley +1 more source
Diagnosis and management of neutropenia in adults: Expert guidance
Severe neutropenia can result from decreased production of neutrophil precursors in the bone marrow, as in the case of severe congenital neutropenia, or from increased utilization of neutrophils or their accelerated destruction as for drug‐induced neutropenia or autoimmune neutropenia. Severe chronic neutropenia increases susceptibility to bacterial or
Karl Welte +5 more
wiley +1 more source
EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. [PDF]
Eichhorst B +13 more
europepmc +1 more source

